Vimarsana
Biggest News Aggregation in the World

Page 43 - Fda Approval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fda Approval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fda Approval Today - Breaking & Trending Today

Abbott Receives FDA Approval for TactiFlex™ Ablation Catheter for Treatment of Abnormal Heart Rhythm - Vimarsana News

Abbott Receives FDA Approval for TactiFlex™ Ablation Catheter for Treatment of Abnormal Heart Rhythm

/PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's TactiFlex™ Ablation Catheter,...

FDA Clears New Insulin Pump and Algorithm-Based Software to Support Enhanced Automatic Insulin Delivery - Vimarsana News

FDA Clears New Insulin Pump and Algorithm-Based Software to Support Enhanced Automatic Insulin Delivery

/PRNewswire/ -- Today, the U.S. Food and Drug Administration cleared the Beta Bionics iLet ACE Pump and the iLet Dosing Decision Software for people six years...

Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases - Vimarsana News

Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases

/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...

Lumen Bioscience granted FDA fast track for C. difficile treatment - Vimarsana News

Lumen Bioscience granted FDA fast track for C. difficile treatment

Lumen Bioscience has announced that the US Food and Drug Administration (FDA) has granted fast track designation for LMN-201, its biologic drug to treat and prevent C. difficile infection (CDI).

SiSaf gets green light from FDA for osteopetrosis treatment - Vimarsana News

SiSaf gets green light from FDA for osteopetrosis treatment

SiSaf has been granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (PRDD) by the US Food and Drug Administration (FDA) for its osteopetrosis treatment, SIS-101-ADO.